| 1/5/2021 |
Testing positive for coronavirus after getting a vaccine? Here's how likely that is and what to know if it happens |
MSN |
... runoffTODAY ‘Republicans across the country’ are counting on Georgia voters: Rep. NunesFOX News GOP pollster says 'the next 48 hours are going to be among the worst' ever for RepublicansCNBC Goldman Sachs CEO on what small businesses still need to survive pandemicCBS News Gupta describes his parents 'camping out' 9 hours for vaccineCNN Jenna Bush Hager reveals her January book club pick: ‘Black Buck ... |
| 1/5/2021 |
2020 SPAC Boom Lifted Wall Street's Biggest Banks - WSJ |
The Wall Street Journal |
... institutions entered the sector, the biggest banks also increased their activity. Two— Credit Suisse Group AG CS 5.13% and Citigroup Inc. C 6.94% —together accounted for nearly 30% of the underwriting, followed by Goldman Sachs Group Inc. GS 5.92%A SPAC is a public firm that uses the money raised from an initial public offering to merge with another company, typically within a few years. That target company then ... |
| 1/3/2021 |
Westlake Chemical (NYSE:WLK) Downgraded to Hold at BidaskClub |
Daily Political |
... shares of Westlake Chemical (NYSE:WLK) from a buy rating to a hold rating in a research report report published on Wednesday, BidAskClub reports.Other analysts also recently issued reports about the company. The Goldman Sachs Group downgraded Westlake Chemical from a buy rating to a neutral rating and boosted their price target for the company from $79.00 to $85.00 in a research note on Sunday, December 13th. UBS Group ... |
| 1/2/2021 |
Becton, Dickinson and Company (NYSE:BDX) Receives $276.92 Consensus Target Price from Brokerages |
Daily Political |
... rating on the stock in a report on Monday, October 12th. TheStreet cut Becton, Dickinson and from a “b” rating to a “c+” rating in a report on Monday, September 21st. The Goldman Sachs Group cut Becton, Dickinson and from a “conviction-buy” rating to a “buy” rating in a report on Tuesday, December 15th. BidaskClub upgraded Becton, Dickinson and from a “hold” rating to ... |
| 1/2/2021 |
Wolters Kluwer (OTCMKTS:WTKWY) Shares Cross Above 50-Day Moving Average of $84.25 |
slatersentinel.com |
... average of $84.25 and traded as high as $87.20. Wolters Kluwer shares last traded at $83.94, with a volume of 7,317 shares trading hands.A number of brokerages have issued reports on WTKWY. The Goldman Sachs Group cut Wolters Kluwer from a “neutral” rating to a “sell” rating in a research note on Monday, November 16th. Zacks Investment Research upgraded Wolters Kluwer from a “sell” rating to ... |
| 1/2/2021 |
Syneos Health (NASDAQ:SYNH) Stock Rating Lowered by BidaskClub |
zolmax.com |
... Saturday, November 21st. Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell upped their price objective on shares of Syneos Health from $75.00 to $80.00 in a report on Wednesday, December 9th. The Goldman Sachs Group raised shares of Syneos Health from a “neutral” rating to a “buy” rating and upped their price objective for the stock from $69.00 to $75.00 in a report on Thursday, October ... |
| 1/1/2021 |
The Goldman Sachs Group Analysts Give AstraZeneca PLC (AZN.L) (LON:AZN) a GBX 6,400 Price Target |
dispatchtribunal.com |
US Crude Prices Plummet 4% as Russia and OPEC Consider Easing CapsThe Goldman Sachs Group set a GBX 6,400 ($83.62) price target on AstraZeneca PLC (AZN.L) (LON:AZN) in a research report released on Monday, Borsen Zeitung reports. The brokerage currently has a sell rating on the biopharmaceutical company’s stock.AZN has been the topic of a number of other research reports. Barclays set a GBX 9,300 ($121.51 ... |
| 1/1/2021 |
The Goldman Sachs Group Reiterates GBX 6,400 Price Target for AstraZeneca PLC (AZN.L) (LON:AZN) |
com-unik.info |
The Goldman Sachs Group Reiterates GBX 6,400 Price Target for AstraZeneca PLC (AZN.L) (LON:AZN) Posted by Trent Williams on Jan 1st, 2021The Goldman Sachs Group set a GBX 6,400 ($83.62) target price on AstraZeneca PLC (AZN.L) (LON:AZN) in a research report sent to investors on Monday morning, Borsen Zeitung reports. The firm currently has a sell rating on the biopharmaceutical company’s stock.A number of other ... |
| 1/1/2021 |
Wall Street closes with gains and new highs in the Dow Jones and S&P 500 • Hello News |
archytele.com |
... At the end of the operations on the New York Stock Exchange, the Dow Jones rose 0.65% or 196.92 points and stood at 30,606.48 integers, driven by large listed companies such as Intel (2.19%), Goldman Sachs (1.61%) and UnitedHealth (1.60%).The selective S&P 500 rose 0.64% or 24.03 to 3,756.07 units, and the Nasdaq Composite Index rose 0.14% or 18.28 points to 12,888.28 units.By sectors, today stood out ... |
| 1/1/2021 |
Wedbush Weighs in on Kinnate Biopharma Inc.'s FY2020 Earnings (NASDAQ:KNTE) |
thelincolnianonline.com |
... commented on the stock. Piper Sandler initiated coverage on shares of Kinnate Biopharma in a research report on Monday. They set an “overweight” rating and a $60.00 price target on the stock. The Goldman Sachs Group initiated coverage on shares of Kinnate Biopharma in a research report on Monday. They set a “buy” rating and a $48.00 price target on the stock. Finally, SVB Leerink started coverage on ... |
| 1/1/2021 |
SVB Leerink Begins Coverage on Kinnate Biopharma (NASDAQ:KNTE) |
baseballnewssource.com |
... also weighed in on KNTE. Piper Sandler started coverage on shares of Kinnate Biopharma in a research report on Monday. They set an overweight rating and a $60.00 target price for the company. The Goldman Sachs Group started coverage on shares of Kinnate Biopharma in a research report on Monday. They set a buy rating and a $48.00 target price for the company. Get Kinnate Biopharma alerts:Shares of NASDAQ ... |
| 1/1/2021 |
SVB Leerink Begins Coverage on Kinnate Biopharma (NASDAQ:KNTE) |
com-unik.info |
... also recently weighed in on KNTE. Piper Sandler assumed coverage on shares of Kinnate Biopharma in a report on Monday. They issued an overweight rating and a $60.00 price target on the stock. The Goldman Sachs Group assumed coverage on shares of Kinnate Biopharma in a report on Monday. They issued a buy rating and a $48.00 price target on the stock. Get Kinnate Biopharma alerts:NASDAQ:KNTE opened at ... |
| 1/1/2021 |
Five Below (NASDAQ:FIVE) Upgraded at BidaskClub |
slatersentinel.com |
... in a research report on Monday, November 30th. Berenberg Bank initiated coverage on Five Below in a research report on Wednesday, November 18th. They issued a “hold” rating on the stock. Finally, The Goldman Sachs Group raised Five Below from a “neutral” rating to a “buy” rating and boosted their target price for the company from $124.00 to $194.00 in a research report on Thursday, December 10th ... |
| 1/1/2021 |
AQR Capital Management LLC Takes $347,000 Position in Phreesia, Inc. (NYSE:PHR) |
theenterpriseleader.com |
... its stake in Phreesia by 5.2% in the 3rd quarter. BlackRock Inc. now owns 2,553,226 shares of the company’s stock valued at $82,034,000 after acquiring an additional 125,665 shares in the last quarter. Goldman Sachs Group Inc. lifted its stake in Phreesia by 67.6% in the 2nd quarter. Goldman Sachs Group Inc. now owns 160,053 shares of the company’s stock valued at $4,526,000 after acquiring an additional 64,579 ... |
| 1/1/2021 |
Outset Medical (NYSE:OM) Shares Up 9.7% |
Daily Political |
... on the stock. Stifel Nicolaus assumed coverage on shares of Outset Medical in a report on Monday, October 12th. They set a “buy” rating and a $54.00 target price on the stock. The Goldman Sachs Group assumed coverage on shares of Outset Medical in a report on Monday, October 12th. They set a “buy” rating and a $54.00 target price on the stock. Finally, SVB Leerink assumed coverage ... |